Lupus & antiphospholipid syndrome
Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab
Authors' conclusion
By linking disease activity measures with PROs, we identified four distinct trajectories describing SLE evolution following the initiation of therapy.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) in four RCTs of belimumab (BLISS-52, BLISS-76, BLISS-SC, EMBRACE) with ≥2 visits and available SLEDAI-2K, British Isles Lupus Assessment Group (BILAG), Physician Global Assessment (PGA), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and GC use dataanalysed
- Participants
- 2,868 patients
- Primary endpoint
- Disease evolution trajectories (latent classes) after treatment initiation
Methodological detailsgrowth mixture modelling, latent class analysis
- Growth mixture modelling
- Latent class analysis
Primary result
As reported in the abstract
Disease evolution trajectories (latent classes)
- Four classes best described disease evolution: highly active, responders; highly active, non-responders; moderately active, responders; moderately active, non-responders
- 4
Further findings
Baseline characteristics
- Disease duration, median (IQR 1.5-9.7), years
- 4.5
- SDI, mean (±SD 2.0)
- 0.7
- SLEDAI-2K, mean (±SD 3.6)
- 10.2
- BILAG, mean (±SD 7.8)
- 17.0
- PGA, mean (±SD 0.5)
- 1.5
- FACIT-F, mean (±SD 11.9)
- 30.6
- Prednisone dose, mean (±SD 8.9), mg/day
- 11.0
Original publication
Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab. Rheumatology (Oxford). Published 16 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →